34 The Journal of Rheumatology 2013; 40:1; doi:10.3899/jrheum.120754 Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved. Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website ZAHI TOUMA, DAFNA D. GLADMAN, ANNE MacKINNON, SIMON CARETTE, MAHMOUD ABU-SHAKRA, ANCA ASKANASE, OLA NIVED, JOHN G. HANLY, CAROLINA LANDOLT-MARTICORENA, LAI-SHAN TAM, SERGIO TOLOZA, MANDANA NIKPOUR, CLAIRE RIDDELL, AMANDA STEIMAN, LIHI EDER, AMIR HADDAD, CLAIRE BARBER, and MURRAY B. UROWITZ ABSTRACT. Objective. To describe the development of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 (S2K RI-50) Website (www.s2k-ri-50.com) and to assess satis- faction with its training and examination modules among rheumatologists and rheumatology fellows. Methods. The development of the Website occurred in 3 phases. The first was a deployment phase that consisted of preparing the site map along with its content. The content included the S2K RI-50 training manual, the tests and corresponding question bank, and the online adaptive training module, along with the extensive site testing. The second phase included the participation of rheumatologists and trainees who completed the Website modules. The third was a quality assurance phase in which an online survey was developed to determine the satisfaction level of its users. Further modifications were implemented per participants’ recommendations. Results. The site has been online since it was registered in September 2010. Fourteen rheumatolo- gists and rheumatology trainees from different centers reviewed and completed the material contained in the Website. The survey revealed acceptance among rheumatologists for the Website’s content, design, and presentation. The Website was rated as user-friendly and useful in familiarizing investigators with the S2K RI-50. After completion of the training and examination modules, parti- cipants reported a suitable level of preparation to implement the S2K RI-50 in clinical trials and research settings in a timely manner. Conclusion. The Website includes training and examination modules that familiarize rheumatolo- gists with the S2K RI-50 and assesses their competence to use the index. This prepares them for the use of the S2K RI-50 in clinical trials and research settings. (First Release Nov 1 2012; J Rheumatol 2013;40:34–9; doi:10.3899/jrheum.120754) Key Indexing Terms: SYSTEMIC LUPUS ERYTHEMATOSUS SRI-50 SRI-50 WEBSITE S2K RI-50 S2K RI-50 WEBSITE From the Institute of Medical Science, the Lupus Clinic, University of Toronto, Toronto, Ontario; Dalhousie Lupus Clinic, Capital Health and Dalhousie University, Halifax, Nova Scotia; University of Calgary, Calgary, Alberta, Canada; the Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel; New York University School of Medicine, New York, New York, USA; University Hospital, Lund, Sweden; The Chinese University of Hong Kong, China; Hospital San Juan Bautista, Catamarca, Argentina; The University of Melbourne, Victoria, Australia; and Antrim Area Hospital, Northern Health and Social Care Trust, Northern Ireland, UK. Dr. Touma is a recipient of the Lupus Ontario Geoff Carr Fellowship and the University of Toronto Arthritis Centre of Excellence Fellowship. The Lupus Clinic is supported by The Lupus Flare Foundation, the Arthritis and Autoimmune Centre Foundation, the Toronto General-Toronto Western Hospital Foundation, and the Smythe Foundation. Z. Touma, MD, FACP, PhD, Institute of Medical Science; D.D. Gladman, MD, FRCPC, Professor of Medicine, Senior Scientist; A. MacKinnon, Coordinator of The Lupus Clinic; S. Carette, MD, MPhil, FRCPC, Professor of Medicine, University of Toronto; M. Abu-Shakra, MD, Professor of Medicine, Head, Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University; A. Askanase, MD, MPH, Assistant Professor, New York University School of Medicine; O. Nived, MD, Assistant Professor, University Hospital; J.G. Hanly, MD, FRCPC, Professor of Medicine and Pathology, Director, Dalhousie Lupus Clinic, Capital Health and Dalhousie University; C. Landolt-Marticorena, MD, PhD, FRCPC, Assistant Professor, Senior Scientist, University of Toronto; L-S. Tam, MD, Professor of Medicine, The Chinese University of Hong Kong; S. Toloza, MD, Hospital San Juan Bautista; M. Nikpour, MBBS, FRACP, FRCPA, PhD, Rheumatologist and Senior Lecturer; C. Riddell, MD, FRCP, Antrim Area Hospital, Northern Health and Social Care Trust; A. Steiman, MD, FRCPC, Institute of Medical Science; L. Eder, MD, PhD; A. Haddad, MD, University of Toronto; C. Barber, MD, FRCPC, University of Calgary; M.B. Urowitz, MD, FRCPC, Professor of Medicine, Senior Scientist, University of Toronto. Address correspondence to Dr. M.B. Urowitz, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Room 1E-409, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada. E-mail: m.urowitz@utoronto.ca Accepted for publication September 25, 2012. www.jrheum.org Downloaded on May 3, 2022 from